Dear Business & Industry Insider,
SPECT has long been nuclear medicine's workhorse modality, though it's been overshadowed in recent years by the rapid growth of PET. Nevertheless, a large installed base of SPECT cameras makes the market an attractive target for developers of new radiopharmaceuticals and devices.
One such company is the subject of this week's Business & Industry Insider. Startup firm Cell>Point is developing a new line of radiopharmaceuticals that it hopes will make SPECT more competitive with PET for oncology applications -- a segment that PET has dominated in recent years.
The company has developed a new method of attaching deoxyglucose, the compound used most commonly in PET studies, to technetium, a SPECT radiotracer that has several advantages over FDG in terms of price and ease of use.
Cell>Point has licensed technology from M. D. Anderson Cancer Center in Houston, and signed a development agreement with one of the major multimodality vendors. It is hoping to launch a series of diagnostic and therapeutic products based on technetium and rhenium.
Learn more about Cell>Point by clicking here. When you're finished, check out the rest of the business news in the medical imaging industry by visiting the Business & Industry Digital Community at business.auntminnie.com.
